BRPI0510043A - método de tratamento de dor neuropática usando antagonista de receptor crth2 - Google Patents

método de tratamento de dor neuropática usando antagonista de receptor crth2

Info

Publication number
BRPI0510043A
BRPI0510043A BRPI0510043-7A BRPI0510043A BRPI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
neuropathic pain
crth2 receptor
treating neuropathic
treating
Prior art date
Application number
BRPI0510043-7A
Other languages
English (en)
Inventor
Laura Corradini
Mark John Field
Ross Anderson Kinloch
Bryn Ivor Williams-Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408799A external-priority patent/GB0408799D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0510043A publication Critical patent/BRPI0510043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODO DE TRATAMENTO DE DOR NEUROPáTICA USANDO ANTAGONISTA DE RECEPTOR CRTH2. A presente invenção refere-se ao uso de um antagonista de receptor de CRTH2 na fabricação de um medicamento para o tratamento de dor neuropática e a um método para tratar dor neuropática utilizando um antagonista de receptor de CRTH2.
BRPI0510043-7A 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2 BRPI0510043A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408799A GB0408799D0 (en) 2004-04-20 2004-04-20 Method of treating pain
US59087104P 2004-07-22 2004-07-22
PCT/IB2005/000992 WO2005102338A1 (en) 2004-04-20 2005-04-08 Method of treating neuropathic pain using a crth2 receptor antagonist

Publications (1)

Publication Number Publication Date
BRPI0510043A true BRPI0510043A (pt) 2007-10-16

Family

ID=34964546

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510043-7A BRPI0510043A (pt) 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2

Country Status (7)

Country Link
US (1) US20090170897A1 (pt)
EP (1) EP1740179A1 (pt)
JP (1) JP2007533725A (pt)
BR (1) BRPI0510043A (pt)
CA (1) CA2563707A1 (pt)
MX (1) MXPA06011891A (pt)
WO (1) WO2005102338A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
ATE524182T1 (de) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-substituierte pyrazinsulfonamide als crth2- hemmer
WO2006125784A1 (en) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Tricyclic spiro derivatives as crth2 modulators
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP1969117A4 (en) * 2005-12-13 2008-12-17 Trinity Lab Inc A method to treat premature ejaculation in humans
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
TR200703092A1 (tr) * 2007-05-08 2008-12-22 SANOVEL �LA� SAN. VE TiC. A.�. Flurbiprofen ve kas gevşetici kombinasyonları
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) * 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009102462A1 (en) 2008-02-15 2009-08-20 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
WO2010092043A1 (en) 2009-02-12 2010-08-19 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010102154A2 (en) 2009-03-05 2010-09-10 Ligand Pharmaceuticals Incorporated Biaryl oxyacetic acid compounds
WO2011002814A2 (en) 2009-06-30 2011-01-06 Ligand Pharmaceuticals Inc. Biaryl oxyacetic acid compounds
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104634906B (zh) * 2013-11-07 2018-07-13 苏州普源精电科技有限公司 分离峰的基线调整方法和具有基线调整功能的色谱工作站
CN104634883B (zh) * 2013-11-07 2018-04-27 苏州普源精电科技有限公司 一种具有融合峰基线调整功能的色谱工作站
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び/又は、治療するためのptgdr−1及び/又はptgdr−2アンタゴニスト
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315230T1 (de) * 1999-08-23 2006-02-15 Bml Inc Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
EP1424335A4 (en) * 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
AU2003269327A1 (en) * 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
JPWO2004052863A1 (ja) * 2002-12-06 2006-04-13 協和醗酵工業株式会社 抗炎症剤
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20050038070A1 (en) * 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators

Also Published As

Publication number Publication date
CA2563707A1 (en) 2005-11-03
WO2005102338A8 (en) 2006-12-14
MXPA06011891A (es) 2007-04-24
EP1740179A1 (en) 2007-01-10
JP2007533725A (ja) 2007-11-22
WO2005102338A1 (en) 2005-11-03
US20090170897A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
BRPI0919876A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
DE602007011908D1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
PT1765314T (pt) Composições farmacêuticas para o tratamento de doenças e sintomas em artrite reumatoide
BRPI0717769A2 (pt) Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF BONE DISEASES
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
ZA200808865B (en) Antibody composition and methods for treatment of neoplastic disease
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
BRPI0509211A (pt) uso de compostos de peptìdeo para o tratamento de dor em neuropatia diabética
BRPI0909651A2 (pt) cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
EP1715820A4 (en) SPINE-facet joint IMPLANT
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0716250A2 (pt) Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
BRPI0921557A2 (pt) bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.